Quanterix Corporation (QTRX)
Stock Price Chart
Key Info
| Market Cap | 1.15B |
| Revenue (ttm) | 59.72M |
| Net Income (ttm) | -44.74M |
| Shares Out | 31.49M |
| EPS (ttm) | -1.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 30, 2020 |
| Last Price | $36.61 |
| Previous Close | $37.85 |
| Change ($) | -1.24 |
| Change (%) | -3.28% |
| Day's Open | 37.33 |
| Day's Range | 36.16 - 37.69 |
| Day's Volume | 119,468 |
| 52-Week Range | 10.90 - 48.95 |
More Stats
| Market Cap | 1.15B |
| Enterprise Value | 1.09B |
| Earnings Date (est) | Nov 5, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 31.49M |
| Float | 22.61M |
| EPS (basic) | -1.60 |
| EPS (diluted) | -1.61 |
| FCF / Share | -1.28 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 769,512 |
| Short Ratio | 2.87 |
| Short % of Float | 3.40% |
| Beta | 1.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 19.30 |
| PB Ratio | 10.90 |
| Revenue | 59.72M |
| Operating Income | -45.66M |
| Net Income | -44.74M |
| Free Cash Flow | -36.35M |
| Net Cash | 59.72M |
| Net Cash / Share | 1.90 |
| Gross Margin | 45.96% |
| Operating Margin | -76.45% |
| Profit Margin | -74.90% |
| FCF Margin | -60.86% |
| ROA | -20.22% |
| ROE | -48.17% |
| ROIC | -103.80% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 56.73 | 37.63 | 22.87 | 17.59 | 12.18 |
| Revenue Growth | 50.76% | 64.52% | 30.08% | 44.38% | - |
| Gross Profit | 26.84 | 17.95 | 9.99 | 7.75 | 5.72 |
| Operating Income | -41.60 | -31.55 | -26.01 | -21.71 | -14.52 |
| Net Income | -40.80 | -31.54 | -27.02 | -23.17 | -15.94 |
| Shares Outstanding | 25.09 | 21.99 | 3.76 | 2.14 | 1.81 |
| Earnings Per Share | -1.63 | -1.43 | -8.30 | -12.89 | -11.19 |
| Operating Cash Flow | -26.19 | -28.72 | -22.11 | -17.74 | -12.52 |
| Capital Expenditures | -10.85 | -1.50 | -1.13 | -0.53 | -0.55 |
| Free Cash Flow | -37.03 | -30.22 | -23.24 | -18.27 | -13.07 |
| Cash & Equivalents | 110 | 45.43 | 79.68 | 29.67 | 2.32 |
| Total Debt | 7.66 | 7.62 | 9.38 | 10.24 | 9.73 |
| Net Cash / Debt | 103 | 37.81 | 70.30 | 19.43 | -7.40 |
| Assets | 170 | 67.61 | 91.78 | 37.12 | 7.35 |
| Liabilities | 41.29 | 26.55 | 25.91 | 23.64 | 22.55 |
| Book Value | 129 | 41.07 | 65.87 | -115 | -88.64 |
Company Profile
Company Details
| Full Name | Quanterix Corporation |
| Country | United States |
| Employees | 248 |
| CEO | E. Kevin Hrusovsky |
Stock Information
| Ticker Symbol | QTRX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: QTRX |
| IPO Date | December 7, 2017 |
Description
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.